A fixed-dose combination of Empagliflozin (SGLT2 inhibitor) and Metformin (biguanide) indicated for the management of type 2 diabetes mellitus. The combination provides complementary mechanisms of action: increased urinary glucose excretion and reduced hepatic glucose production.
Reviews
There are no reviews yet.